Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus NICLOCIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus NICLOCIDE.
ALBENZA vs NICLOCIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Category C
Category C
Anthelmintic
Anthelmintic